197 related articles for article (PubMed ID: 29044660)
1. Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab.
Mohr P; Ascierto P; Arance A; McArthur G; Hernaez A; Kaskel P; Shinde R; Stevinson K
J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):962-971. PubMed ID: 29044660
[TBL] [Abstract][Full Text] [Related]
2. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study.
Russi A; Damuzzo V; Chiumente M; Pigozzo J; Cesca M; Chiarion-Sileni V; Palozzo AC
J Chemother; 2017 Aug; 29(4):245-251. PubMed ID: 28398170
[TBL] [Abstract][Full Text] [Related]
4. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.
Failing JJ; Finnes HD; Kottschade LA; Allred JB; Markovic SN
Melanoma Res; 2016 Dec; 26(6):609-615. PubMed ID: 27603551
[TBL] [Abstract][Full Text] [Related]
5. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.
Jochems A; Leeneman B; Franken MG; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; Groenewegen G; de Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Koornstra RH; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; Uyl-de Groot CA; van der Hoeven KJM
Anticancer Drugs; 2018 Jul; 29(6):572-578. PubMed ID: 29659371
[TBL] [Abstract][Full Text] [Related]
6. A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma.
Drysdale E; Peng Y; Nguyen P; Baetz T; Hanna TP
Melanoma Res; 2019 Dec; 29(6):635-642. PubMed ID: 30789386
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study.
Urun Y; Yasar HA; Turna H; Esin E; Sedef AM; Alkan A; Oksuzoglu B; Ozdemir N; Sendur MN; Sezer A; Kılıckap S; Utkan G; Akman T; Akbulut H; Celik I; Abalı H
J Oncol Pharm Pract; 2019 Oct; 25(7):1658-1664. PubMed ID: 30400750
[TBL] [Abstract][Full Text] [Related]
8. Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.
Joseph RW; Shillington AC; Lee TA; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Scherrer E; Liu FX
J Med Econ; 2020 Feb; 23(2):132-138. PubMed ID: 31750751
[No Abstract] [Full Text] [Related]
9. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
[TBL] [Abstract][Full Text] [Related]
10. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up.
Aamdal E; Jacobsen KD; Straume O; Kersten C; Herlofsen O; Karlsen J; Hussain I; Amundsen A; Dalhaug A; Nyakas M; Schuster C; Hagene KT; Holmsen K; Russnes HG; Skovlund E; Kaasa S; Aamdal S; Kyte JA; Guren TK
Int J Cancer; 2022 Jan; 150(1):100-111. PubMed ID: 34449877
[TBL] [Abstract][Full Text] [Related]
12. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
Middleton MR; Dalle S; Claveau J; Mut P; Hallmeyer S; Plantin P; Highley M; Kotapati S; Le TK; Brokaw J; Abernethy AP
Cancer Med; 2016 Jul; 5(7):1436-43. PubMed ID: 27118102
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Balatoni T; Ladányi A; Fröhlich G; Czirbesz K; Kovács P; Pánczél G; Bence E; Plótár V; Liszkay G
Pathol Oncol Res; 2020 Jan; 26(1):317-325. PubMed ID: 30225783
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab prolongs survival in advanced melanoma.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
[No Abstract] [Full Text] [Related]
17. Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma.
Mangana J; Dimitriou F; Braun R; Ludwig S; Dummer R; Barysch MJ
Melanoma Res; 2019 Dec; 29(6):648-654. PubMed ID: 30870270
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.
Eggermont AMM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbe C; Ferraresi V; Smylie M; Weber JS; Maio M; Hosein F; de Pril V; Kicinski M; Suciu S; Testori A
Eur J Cancer; 2019 Sep; 119():1-10. PubMed ID: 31400634
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D
Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.
Jung M; Lee J; Kim TM; Lee DH; Kang JH; Oh SY; Lee SJ; Shin SJ
Cancer Res Treat; 2017 Jan; 49(1):44-53. PubMed ID: 27121719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
